The board of directors of CStone Pharmaceuticals also announced that Dr. Frank Ningjun Jiang, after leading CStone's development for six years, had decided to retire from and will cease to serve as the CEO, in effect from August 25, 2022. Dr. Jiang will serve as the Senior Advisor of the Company until the end of 2022 to ensure a smooth transition of the Company's operations. The Board announced that Dr. Jianxin Yang, the Senior Vice President and Chief Medical Officer of the Company, has been appointed as the CEO, in effect from August 25, 2022.

The Board takes this opportunity to welcome Dr. Jianxin Yang to his new appointments. Dr. Yang, M.D., Ph.D., has been the Company's Senior Vice President and Chief Medical Officer since December 2016. In this role, he was responsible for developing and implementing the overall clinical strategy.

Dr. Yang has over 25 years of experience in biomedical research and clinical development of oncology drugs in the U.S. and China. Throughout his career, Dr. Yang has made significant contributions to the successful development of several anticancer drugs. He is also the author of over 50 publications and the inventor of 9 patents.

Dr. Yang received a bachelor's degree in medicine from Xianning Branch of Hubei Medical College, (currently known as Hubei Institute of Science and Technology) in Hubei, China in July 1985 and a master's degree in pathophysiology from Nanjing Medical College, (currently known as Nanjing Medical University) in Nanjing, China in July 1989. He then received his Ph.D. training in molecular biology with Nobel Laureates Drs. Michael S. Brown and Joseph L. Goldstein at the University of Texas Southwestern Medical Center at Dallas, U.S. in June 1995.

He conducted his postdoctoral training in chemical biology with Dr. Stuart L. Schreiber at Harvard University in the United States from 1995 to 1998.